Literature DB >> 6639222

Octylonium bromide: a smooth muscle relaxant which interferes with calcium ions mobilization.

C A Maggi, S Manzini, A Meli.   

Abstract

A series of "in vitro" experiments have been carried out to determine the mechanisms(s) responsible for the smooth muscle relaxant properties exhibited by octylonium bromide. Unlike N-butyl-scopolammonium bromide, octylonium bromide possesses both competitive and non competitive antimuscarinic and antihistaminic properties. Pretreatment of ileal segments with dibenamie, which destroyed muscarinic spare receptors, revealed the non competitive nature of octylonium bromide antagonism. The competitive antagonism toward BaCl2-induced contraction of rat ileum and aorta suggested that octylonium bromide interferes with Ca++ mobilization. As compared with verapamil a known Ca++ entry blocker and unlike it, octylonium bromide is more effective in antagonizing Ca++-induced contraction in K+ depolarized rat colon than aorta. Both octylonium bromide and verapamil reduced in a concentration-dependent manner the tonic contraction produced by exposure to high K+ of rat duodenum and rabbit ear artery. Both octylonium bromide and verapamil antagonized carbachol-induced phasic plus sustained tonic contraction of rat colon in high K+ Ca++-free medium. Unlike octylonium bromide, verapamil antagonized the phasic contraction only and inhibition of the overall contraction did not exceed 60%. Unlike verapamil, octylonium bromide antagonized norepinephrine-induced contraction of rabbit ear artery in high K+ C++-free medium. Interference with mobilization of cellular and extracellular Ca++ pools produced by different neurohormones is likely to be the mechanism responsible for octylonium bromide smooth muscle relaxant properties in both animals and humans.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6639222

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  6 in total

1.  The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts.

Authors:  Susanne Lindqvist; James Hernon; Paul Sharp; Neil Johns; Sarah Addison; Mark Watson; Richard Tighe; Shaun Greer; Jean Mackay; Michael Rhodes; Michael Lewis; William Stebbings; Chris Speakman; Stefano Evangelista; Ian Johnson; Mark Williams
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Is otilonium bromide really effective for treating asian patients with irritable bowel syndrome?

Authors:  Ji Won Kim
Journal:  J Neurogastroenterol Motil       Date:  2012-01-16       Impact factor: 4.924

3.  Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells.

Authors:  L Gandía; M Villarroya; B Lara; V Olmos; J A Gilabert; M G López; R Martínez-Sierra; R Borges; A G García
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

Review 4.  Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.

Authors:  Jakub Rychter; Francisco Espín; Diana Gallego; Patri Vergara; Marcel Jiménez; Pere Clavé
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

5.  Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide.

Authors:  F Narducci; G Bassotti; M T Granata; M A Pelli; M Gaburri; R Palumbo; A Morelli
Journal:  Dig Dis Sci       Date:  1986-03       Impact factor: 3.199

Review 6.  IBS and the role of otilonium bromide.

Authors:  Guy Boeckxstaens; Enrico S Corazziari; Fermín Mearin; Jan Tack
Journal:  Int J Colorectal Dis       Date:  2012-11-22       Impact factor: 2.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.